Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100032, China; Department of Rehabilitation, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100071, China.
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100032, China.
J Integr Med. 2024 Mar;22(2):163-179. doi: 10.1016/j.joim.2024.03.003. Epub 2024 Mar 6.
Ginkgo biloba L. preparations (GBLPs) are a class of Chinese herbal medicine used in the adjuvant treatment of ischemic stroke (IS). Recently, several systematic reviews (SRs) and meta-analyses (MAs) of GBLPs for IS have been published.
This overview aims to assess the quality of related SRs and MAs.
PubMed, Embase, Cochrane Library, Web of Science, Chinese Biological Medicine, China National Knowledge Infrastructure, Wanfang, and Chinese Science and Technology Journals databases were searched from their inception to December 31, 2022.
SRs and MAs of randomized controlled trials (RCTs) that explored the efficacy of GBLPs for patients with IS were included.
Two independent reviewers extracted data and assessed the methodological quality, risk of bias (ROB), reporting quality, and credibility of evidence of the included SRs and MAs using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2), Risk of Bias in Systematic Reviews (ROBIS), the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), and the Grading of Recommendations Assessment, Development and Evaluation (GRADE), respectively. Additionally, descriptive analysis and data synthesis were conducted.
Twenty-nine SRs/MAs involving 119 outcomes were included in this review. The overall methodological quality of all SRs/MAs was critically low based on AMSTAR 2, and 28 had a high ROB based on the ROBIS. According to the PRISMA statement, the reporting items of the included SRs/MAs are relatively complete. The results based on GRADE showed that of the 119 outcomes, 8 were rated as moderate quality, 24 as low quality, and 87 as very low quality. Based on the data synthesis, GBLPs used in conjunction with conventional treatment were superior to conventional treatment alone for decreasing neurological function scores.
GBLPs can be considered a beneficial supplemental therapy for IS. However, because of the low quality of the existing evidence, high-quality RCTs and SRs/MAs are warranted to further evaluate the benefits of GBLPs for treating IS. Please cite this article as: Meng TT, You YP, Li M, Guo JB, Song XB, Ding JY, Xie XL, Li AQ, Li SJ, Yin XJ, Wang P, Wang Z, Wang BL, He QY. Chinese herbal medicine Ginkgo biloba L. preparations for ischemic stroke: An overview of systematic reviews and meta-analyses. J Integr Med. 2024;22(2): 163-179.
银杏叶制剂（GBLPs）是一类用于辅助治疗缺血性脑卒中（IS）的中药。最近，已经发表了几项关于银杏叶制剂治疗 IS 的系统评价（SR）和荟萃分析（MA）。
本综述旨在评估相关 SR 和 MA 的质量。
从建库至 2022 年 12 月 31 日，检索了 PubMed、Embase、Cochrane 图书馆、Web of Science、中国生物医学文献数据库、中国知网、万方和中国科技期刊数据库。
纳入了探讨银杏叶制剂治疗 IS 患者疗效的随机对照试验（RCT）的 SR 和 MA。
两名独立的综述作者使用 AMSTAR 2、ROBIS、PRISMA 和 GRADE 分别提取数据并评估纳入的 SR 和 MA 的方法学质量、偏倚风险（ROB）、报告质量和证据可信度。此外，还进行了描述性分析和数据综合。
本综述共纳入 29 项 SR/MA，涉及 119 个结局。所有 SR/MA 的总体方法学质量根据 AMSTAR 2 评估为极低，根据 ROBIS 评估有 28 项为高 ROB。根据 PRISMA 声明，纳入的 SR/MA 的报告项目相对完整。基于 GRADE 的结果显示，在 119 个结局中，8 个为中度质量，24 个为低质量，87 个为极低质量。基于数据综合，银杏叶制剂联合常规治疗在降低神经功能评分方面优于常规治疗单独使用。
银杏叶制剂可被视为 IS 的一种有益的辅助治疗方法。然而，由于现有证据质量较低，需要进行高质量的 RCT 和 SR/MA 来进一步评估银杏叶制剂治疗 IS 的益处。请引用本文：孟腾腾，尤艳萍，李敏，郭静波，宋晓彬，丁建英，谢晓亮，李爱琴，李圣杰，殷晓静，王鹏，王震，王柏力，贺启荣。中药银杏叶制剂治疗缺血性脑卒中：系统评价和荟萃分析概述。中国整合医学杂志。2024；22（2）：163-179。
